Turkey \l=C;\elik I, Akalin S, Erba\l=s;\T. Serum levels of interleukin 6 and tumor necrosis factor-\g=a\in hyperthyroid patients before and after propylthiouracil treatment. Eur J Endocrinol 1995;132:668\p=n-\72.ISSN 0804\p=n-\ 4643 Contrary to the usual inhibitory role of tumor necrosis factor-\g=a\ (TNF-\g=a\) thyroid metabolism, it also has specific stimulatory effects in autoimmune thyroid disorders, including induction of HLA class II antigen-presenting cell\p=m-\Tcell interaction. Despite high intrathyroidal concentrations, various studies were not able to demonstrate high serum levels of TNF-\g=a\in patients with Graves' disease. To investigate this discrepancy we determined TNF-\g=a\and interleukin 6 (IL-6) levels in 25 hyperthyroid patients who responded to propylthiouracil treatment (16 with Graves' disease and nine with toxic multinodular goiter) and compared them with the levels found in euthyroid patients with simple diffuse goiter (n = 15) and normal healthy controls (n = 15). Median IL-6 levels were high in both Graves' disease and toxic multinodular goiter patients before propylthiouracil treatment (23 and 26.5 pg/ml, respectively). After restoring euthyroidism there was a statistically significant decline to near-normal levels (3 and 10 pg/ml, respectively). On the other hand, median serum TNF-\g=a\ levels were high only in Graves' disease patients (20pg/ml) and could not be normalized with antithyroid medication (20 pg/ml) compared to that of controls (5 pg/ml). Tumor necrosis factor-\g=a\, but not IL-6, was found to be high in the sera of Graves' disease patients when euthyroid, which may be due to an ongoing antigen\p=n-\antibody interaction, a feature of autoimmune attack. It remains to be determined whether the degree of TNF-\g=a\ and/or IL-6 elevation will be a predictor of disease recurrence.
.
Intrathyroidal cytokine production is not restricted to thyroid-infiltrating mononuclear cells; it may also involve thyroid follicular cells (4) . In particular, thyroid cells have been found to produce interleukin 6 (IL-6) (5) . This is a cytokine with key roles in cell terminal differentiation and cell activation (6) . Although intrathyroidal ÍL-6 (8) . Furthermore, TNF-influences growth and function of these cells (9 (4, 10) and serum levels have been detected within the normal range (11) .
The aim of this study was to investigate the serum levels of cytokines and to determine how levels would be effected by treatment with propylthiouracil (PTU). Patients (Fig. 1) .
In GD patients median levels of TNF-before and after treatment were statistically higher (p < 0.001) than controls and non-toxic diffuse goiter patients. In this group, TNF-levels before and after treatment showed a steady-state pattern despite antithyroid treatment. Similar to TMNG patients, fL-6 levels of these patients were significantly high before treatment and declined to a level comparable to controls following treatment (Fig. 1 (10) . Similarly, several studies were not able to detect increased cytokine concentrations in the circulation and argued that tissue levels were not reflected in serum concentrations (4, 11) . The discrepancy between previous studies and our study may be due to the use of a different methodology and a smaller patient group (4, 7, 11) (16, 17) . The altered cell activation profile and restoration of euthyroidism may be associated with reduced IL-6 levels but, as shown in this study, it does not seem to affect TNF-levels.
In conclusion, serum levels of 
